




## Curriculum Vitae

Personal Information	
Title	Dr
Name	Yoon-Kyo An
Degree	BMedSc, MBBS, MBA
Country	Australia
Affiliation	Mater Hospital Brisbane The University of Queensland
E-mail	Yoon.An(at)mater.uq.edu.au
	
Educational Background	
<ul style="list-style-type: none"> <li>• <b>2021:</b> Oxford Executive Leadership Programme, University of Oxford Said Business School, UK</li> <li>• <b>2019 – 2021:</b> Mater of Business Administration (MBA), Griffith University, AUS</li> <li>• <b>2018 – 2024:</b> Doctor of Philosophy (PhD) candidate, The University of Queensland, AUS</li> <li>• <b>2018:</b> Fellow of the Royal Australian College of Physicians (FRACP), AUS</li> <li>• <b>2011:</b> Bachelor of Medicine, Bachelor of Surgery (MBBS), The University of Queensland, AUS</li> <li>• <b>2005:</b> Bachelor of Medical Science (BMedSc), The University of Sydney, AUS</li> </ul>	
Professional Career	
<p>Dr An is an active Inflammatory Bowel Disease (IBD) clinician and researcher. She is the head of IBD at Mater Hospital Brisbane and the clinical lead of IBD clinical trials unit at Mater research, a world class centre of clinical and research excellence. She also holds a senior lecturer position at the University of Queensland. Dr An currently serve on the Gastroenterology Network of Intestinal Ultrasound (GENIUS) committee [chair], Intestinal Bowel Ultrasound Group (IBUS) collaboration committee, Gastroenterological Society of Australia (GESA) committee – young GESA [chair] and GESA AGW Scientific program Committee, Gastroenterological Society of Queensland (GESQ) Committee [board], Royal Australasian College of Physicians (RACP) College Council [Gastroenterology representative], Australian and New Zealand IBD (ANZIBD) consortium and represent Australia at the Asia-Pacific, Middle East and Africa (APMA) IBD Coalition. She has a national and international presence through her numerous symposia and conference presentations.</p>	
Research Field	
<p>Dr An's research focusses on the real-world effectiveness of biologic and targeted synthetic therapy in IBD, and the use of non-invasive monitoring (including biomarkers and intestinal ultrasound) of disease activity to help predict response to therapy. Her study on the effectiveness of faecal calprotectin testing was the basis for its inclusion on the Medicare Benefits Schedule, which represents a significant improvement in clinical care of IBD patients in Australia.</p>	
Main Scientific Publications	
<p>[1] Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. <i>J Gastroenterol Hepatol</i>. 2018;33(7):1347-52.</p> <p>[2] Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, et al. Systematic review and meta-analysis: Optimal salvage therapy in acute severe ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2019;25(7):1169-86.</p> <p>[3] An YK, Prince D, Gardiner F, Neeman T, Linedale EC, Andrews JM, et al. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: Systematic review and meta-analysis. <i>Med J Aust</i>. 2019;211(10):461-7.</p> <p>[4] Rajagopalan A, Sathananthan D, An YK, Van De Ven L, Martin S, Fon J, et al. Gastrointestinal ultrasound</p>	



in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. *JGH Open*. 2020;4(2):267-72.

- [5] Flanagan E, Wright EK, Begun J, Bryant RV, An YK, Ross AL, et al. Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. *J Crohns Colitis*. 2020;14(10):1405-12.
- [6] Haifer C, Srinivasan A, An YK, Picardo S, van Langenberg D, Menon S, et al. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: A multicentre, parallel cohort study. *Med J Aust*. 2021;214(3):128-33.
- [7] An YK. Common mistakes with steroids. *J Gastroenterol Hepatol*. 2021;36 Suppl 1:30-1.
- [8] De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, et al. Higher anti-tumor necrosis factor-alpha levels correlate with improved radiologic outcomes in crohn's perianal fistulas. *Clin Gastroenterol Hepatol*. 2022;20(6):1306-14.
- [9] Malloy R, Fernandes R, Begun J, An YK. Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. *BMJ Case Rep*. 2022;15(12).
- [10] Gilmore R, Tan L, Fernandes R, An YK, Begun J. Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. *J Crohns Colitis*. 2023.